secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monopar Therapeutics (MNPR)
CIK:        0001645469
Form:       8-K
Filed at:   2024-02-20T23:59:59+00:00
Accession:  0001437749-24-004724
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Monopar receives Australian ethics clearance to start Phase 1 trial of radiopharmaceutical MNPR-101-Zr
--------------------------------------------------------------------------------

- HREC clearance in Australia to commence Phase 1 dosimetry trial of MNPR-101-Zr for advanced cancers.
- Trial will enroll ~12 patients using PET imaging to assess tumor uptake, biodistribution, and safety.
- MNPR-101-Zr is a zirconium-89 labeled version of Monopar's uPAR-targeting antibody; preclinical data showed selective uptake.
- If Phase 1 encouraging, Monopar plans to evaluate therapeutic version bound to actinium-225 (Ac-225).
- This is Monopar's first human clinical trial using its uPAR targeting agent.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645469/000143774924004724/0001437749-24-004724-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645469/000143774924004724/mnpr20240216_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-004724

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer